Thomas John C.'s most recent trade in Krystal Biotech Inc was a trade of 1,000 Common Stock done at an average price of $179.3 . Disclosure was reported to the exchange on June 25, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Krystal Biotech Inc | John Charles Thomas | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 179.25 per share. | 25 Jun 2026 | 1,000 | 1,000 (0%) | 0% | 179.3 | 179,250 | Common Stock |
| Krystal Biotech Inc | John Charles Thomas | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 347.27 per share. | 25 Jun 2026 | 1,000 | 0 (0%) | 0% | 347.3 | 347,270 | Common Stock |
| Krystal Biotech Inc | John Charles Thomas | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2026 | 1,000 | 6,500 | - | - | Stock Option (Right to Buy) | |
| Dogwood Therapeutics Inc | John C. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2026 | 16,800 | 16,800 | - | - | Stock Option (right to buy) | |
| Krystal Biotech Inc | John Charles Thomas | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 302.03 per share. | 26 May 2026 | 642 | 0 (0%) | 0% | 302.0 | 193,903 | Common Stock |
| Dogwood Therapeutics Inc | John C. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2025 | 2,362 | 2,362 | - | - | Stock Option (right to buy) | |
| Dogwood Therapeutics Inc | John C. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 210 | 210 | - | - | Stock Option (right to buy) | |
| Dogwood Therapeutics Inc | John C. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 210 | 420 | - | - | Stock Option (right to buy) | |
| Dogwood Therapeutics Inc | Thomas John C. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 4,167 | 4,167 | - | - | Stock Option (right to buy) | |
| Dogwood Therapeutics Inc | John C. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 5,250 | 5,250 | - | - | Stock Option (right to buy) | |
| Dogwood Therapeutics Inc | John C. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 5,250 | 5,250 | - | - | Stock Option (right to buy) | |
| Dogwood Therapeutics Inc | John C. Thomas | Director | Purchase of securities on an exchange or from another person at price $ 5.65 per share. | 04 Jan 2022 | 1,000 | 1,000 | - | 5.7 | 5,650 | Common Stock |
| ImmunityBio Inc | John C. Thomas | Former Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2021 | 5,000 | 202,477 | - | 0 | Common Stock |